On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
The FDA recently approved the first gene therapy for pediatric patients with SMA, signifying a major step forward for the therapeutic field as a whole. To continue this progress, it is important that we understand the key principles and events in gene therapy’s history that have led us to where we are today.
Last month at WRIB, our scientific team had the opportunity to participate in a number of discussions surrounding the latest topics of interest in biomarkers, immunogenicity, and regulatory standards. We wanted to share some of the event takeaways we found most interesting and valuable.
In our latest Team Q&A blog, we talk to Charlie Walker, Associate Director of Finance at BioAgilytix, to learn more about his role, why he felt drawn to the bioanalytical industry, and how he gets to see the team’s work play out in exciting ways, and for the benefit of patients in need.
Flow cytometry is an ideal platform for many applications involving the study of complex cell populations. In the first blog of our new “The Fit for Flow” series, we discuss what makes flow cytometry the platform of choice for receptor occupancy (RO) studies.
Couldn’t make the Oxford Global’s 14th Annual Biomarkers Congress? Read our recap of the key opportunities and challenges in biomarker development that scientists discussed.
When assessing biomarkers for multifactorial diseases, we ideally want to assess multiple analytes in the same experiment. That is where the value of multiplex biomarker analysis comes in – but this method also inherently creates potential challenges with cross-reactivity. We discuss how the ProteinSimple Ella platform enables multiplexing with excellent assay reproducibility, and how it can benefit studies with low sample volumes.
Today we’re featuring a case study on how BioAgilytix developed a cell-based assay to determine the prevalence of pre-existing antibodies against the AAV9 serotype in patients for a gene therapy clinical trial.
In this Q&A session we talk to David Rusnak, one of the first 3 employees to join BioAgilytix when it was founded 10 years ago and currently our Director of Laboratory Systems and Automation, to learn more about his experience growing with the organization from its very start – and what still keeps him excited to come to work each day.
In this Q&A session, we speak to longtime BioAgilytix Europe team member Gabi Schewe – who has been with the company since its founding as IPM Biotech in 1996 – to hear about the exciting and historic scientific advancements she has been part of with the company and what she believes has made its long-term success possible.